Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 83.42
-4.8 %
$ 8.84 B
Market Cap
-100.51
P/E
CASH FLOW STATEMENT
-124 M
OPERATING CASH FLOW
106 M
INVESTING CASH FLOW
17.8 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Intra-Cellular Therapies, Inc.
| Net Income | -140 M |
| Depreciation & Amortization | 528 K |
| Capital Expenditures | -269 K |
| Stock-Based Compensation | 52.8 M |
| Change in Working Capital | -29.6 M |
| Others | 26.2 M |
| Free Cash Flow | -124 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Mar-2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||
| Net Income | (139.7) | (256.3) | (284.1) | (227.0) | (147.7) | (155.1) | (97.8) | (116.4) | (104.8) | (30.7) | (26.9) | (16.6) |
| Depreciation & Amortization | 0.5 | 0.7 | 0.5 | 0.5 | 0.5 | 0.4 | 0.2 | 0.2 | 0.1 | 25.5 K | 23.2 K | 47.7 K |
| Deferred Income Tax | 0 | 0 | (4.1) | (0.6) | (1.1) | 529.2 | (1 058.4) | 0.5 | 0.7 | 0.3 | (0.4) | 0 |
| Stock Based Compensation | 52.8 | 43.0 | 34.3 | 24.1 | 20.8 | 17.4 | 14.6 | 14.7 | 10.9 | 3.8 | 0.4 | 0.3 |
| Other Operating Activities | (8.3) | 0.5 | 0.2 | 0.2 | 0.2 | (530.0) | 1 059.1 | 0.2 | 0.2 | 0.2 | 0.4 | (2.4) |
| Change in Working Capital | (29.6) | (58.1) | (6.4) | (27.3) | (0.6) | 19.9 | 1.8 | 9.5 | (9.4) | 3.5 | 3.9 | (2.7) |
| Cash From Operations | (124.2) | (270.2) | (259.5) | (230.1) | (128.0) | (118.2) | (80.5) | (91.3) | (102.3) | (22.8) | (22.6) | (18.9) |
| INVESTING CASH FLOW | ||||||||||||
| Capital Expenditures | (0.3) | (0.8) | (0.3) | (0.3) | (0.7) | (0.4) | (0.7) | 49 K | (0.9) | 11.8 K | 33.3 K | 39 K |
| Other Items | 105.8 | (127.6) | 280.7 | (480.0) | 178.1 | 135.0 | (92.0) | 92.3 | (360.9) | (66.7) | 1.5 | 5.7 |
| Cash From Investing Activities | 105.5 | (128.4) | 280.3 | (480.3) | 177.4 | 134.6 | (92.7) | 92.3 | (361.8) | (66.7) | 1.5 | 5.7 |
| FINANCING CASH FLOW | ||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 K | 31.1 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 17.8 | 21.4 | 11.5 | 11.5 | 3.2 | 0.7 | 0.3 | 0.5 | (0.1) | (0.5) | 40.5 | 15.2 |
| Cash From Financing Activities | 17.8 | 455.2 | 11.5 | 664.2 | 3.2 | 0.7 | 162.4 | 0.5 | 449.9 | 115.7 | 40.6 | 15.2 |
| CHANGE IN CASH | ||||||||||||
| Net Change In Cash | (0.8) | 56.6 | 32.3 | (46.2) | 52.7 | 17.2 | (10.9) | 1.5 | (14.2) | 26.2 | 19.5 | 2.0 |
| FREE CASH FLOW | ||||||||||||
| Free Cash Flow | (124.5) | (271.0) | (259.9) | (230.3) | (128.7) | (118.6) | (81.2) | (91.3) | (103.1) | (22.8) | (22.6) | (18.9) |